News | April 21, 2015

First Irish Patient Treated for Prostate Cancer in Prague

Proton Therapy Center Czech uses seed markers for precise tumor targeting across five treatments

Proton Therapy Center Czech, John, Irish, U.K., prostate cancer

April 21, 2015 — The Proton Therapy Center in the Czech Republic treated its first Irish patient for prostate cancer beginning in mid-March.

The PTC is well known to the U.K. audience thanks to the story of the British boy Ashya King. Ashya’s parents chose Prague for his brain tumor treatment to ensure the lowest possible side effects. 

But from the U.K. it is mostly men in their fifties and sixties who come for the proton beam therapy in Prague. That's because proton therapy is highly beneficial for the major male problem of prostate cancer. 

John is 64. His family and background is in Ireland and he often still returns to his home country. He came to the U.K. to work, for more than 25 years, for the military forces.

"I was on active surveillance for 18 months back home but felt like I was awaiting something to happen“, said John, describing his feelings of uncertainty. "At that time, I came across the stories of British patients treated in Prague and sat down to read PTC websites and watch the great videos of the center, located in a city I always wanted to visit. Of course there was also the story of Ashya King in the British media. “ 

John did not hesitate and decided for himself. "I just rang the head nurse of my urologist and announced that I was going for proton therapy. I got a message that the urologist was fine with that." Getting all the medical reports took a bit longer than he had imagined – it was Christmas time. "Once I had my folder I sent it to PTC. There the patient manager called Lucie immediately got in touch. She was very supportive and in constant touch. “

John had never visited Prague although he had always wanted to. He and his wife were impressed. "I liked [the] center from day one”, he said. That was when he came for his first consultation and planning of computed tomography (CT) and magnetic resonance imaging (MRI) scans. Then he went back to the U.K. to get some things sorted and came back in mid-March to start his five sessions of treatment.

It consisted of five fractions only – a major advantage of proton beam therapy which enables higher doses onto the tumor, increasing the efficiency and minimizing the unwanted dose around the tumor. “In early stage cases of prostate cancer, PTC Czech has 97 percent curability and the data corresponds to the world clinical studies on proton therapy,” added Jiri Kubes, M.D., PTC medical director. This is also strengthened by the use of golden seeds – golden markers which help to target the beam even more precisely. These golden pellets are applied directly at PTC.

“So far I feel great,” said John.

For more information: www.proton-cancer-treament.com

Related Content

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI.

MRI Targeted biopsy is performed using cognitive fusion more easily with anatomical guidance based on the radiology report. MRI targets can be identified quickly in real-time along with micro-ultrasound targets, which may have been missed on MRI. Image courtesy of Exact Imaging

Feature | Prostate Cancer | January 20, 2021 | By Brian Wodlinger, Ph.D.
Historically when a patient had an elevated PSA (prostate specific antigen) test their urologist would take the next
The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

The exceptionally high dose rate of the FLASH Beam is 3,000 times higher than normal therapy treatment (300 Gray per second vs. 0.1 Gray per second, Gray being a standard unit measuring absorbed radiation). Instead of treatment over 20 seconds, an entire treatment is completed in 6 milliseconds, giving the therapy its nickname, "FLASH." Image courtesy of Brian Pogue, PhD

News | Linear Accelerators | January 20, 2021
January 20, 2021 — A joint team of researchers from Radiation Oncology at Dartmouth's and...
Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
The "US Prostate Cancer Nuclear Medicine Diagnostics Market to 2027 - Country Analysis and Forecast by Type; PET Product" report has been added to ResearchAndMarkets.com's offering. The prostate cancer nuclear medicine diagnostics market in the US was valued at $194.47M in 2019 and is expected to grow at a CAGR of 10.6% from 2020 to 2027 to reach $431.76M by 2027.

Getty Images

News | Prostate Cancer | January 13, 2021
January 13, 2021 — The ...
A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

A study led by researchers at the UCLA Jonsson Comprehensive Cancer Center has found that magnetic resonance imaging, or MRI, frequently underestimates the size of prostate tumors, potentially leading to undertreatment.

News | Prostate Cancer | January 11, 2021
January 11, 2021 — A study
Mirion Technologies, Inc., a global provider of innovative radiation detection and measurement solutions, announced that it has acquired Sun Nuclear Corporation. Sun Nuclear is the global leader in radiation oncology quality assurance, delivering patient safety solutions for diagnostic imaging and radiation therapy centers around the world.
News | Quality Assurance (QA) | January 08, 2021
January 8, 2021 — Mirion Technologies, Inc., a global provider of
RAD Technology Medical Systems (RAD) announced it is expanding its portfolio of patented modular healthcare solutions in 2021 with the introduction of a compact shielding facility designed to accommodate the latest models of low energy, self-shielded linear accelerators (linacs) that are now available worldwide. 

Image courtesy of Siemens Healthineers

News | Linear Accelerators | January 04, 2021
January 4, 2021 — RAD Technology Medical Systems (RAD) ann
RaySearch Laboratories AB has launched the latest release of its widely adopted treatment planning system. RayStation 10B adds support for brachytherapy planning and a new GPU Monte Carlo algorithm, which typically cuts final dose computation times to less than five seconds.
News | Brachytherapy Systems | December 29, 2020
December 29, 2020 — RaySearch Laboratories AB has launched the latest release of its widely adopted treatment plannin
C-RAD has been selected as the partner to implement surface tracking technology for three proton cancer treatment centers in the U.S.
News | Proton Therapy | December 28, 2020
December 28, 2020 — C-RAD offers a specific version of its Catalyst System for use in...
According to recent studies, an increase in the COVID-19 positivity rate correlates to an increase in mortality from non-coronavirus-related diseases. This includes breast cancer, and researchers believe fear of contracting the virus compels patients to stay home instead of completing their post-lumpectomy radiotherapy regimens.

Image courtesy of Zeiss

News | Radiation Therapy | December 21, 2020
December 21, 2020 — According to recent studies, an increase in the...